ADBAC C12-C16 and delay techniques: Is the risk worth the cost?

 

With the upcoming BPR (Biocidal Products Regulation) deadlines for ADBAC C12-C16, many manufacturers are considering “delay techniques.”

What does this entail? Simply put, it involves adding an active substance that is still under BPR review process, to an existing formulation, to postpone the need for BPR dossier preparation and submission.

Sounds like a clever solution? On the surface, perhaps. But is it truly worth the risk?

 

Costs, risks, and uncertainty – The hidden pitfalls of delay techniques

• Significant costs: Reformulation means new efficacy and stability studies, national registrations and certifications. This generates enormous expenses, without any guarantee of success.

• Risk of non-approval: The added active substance may not be approved, or it may be approved with restrictions, rendering the entire product non-compliant.

• Uncertain future: There's no telling how long the evaluation of the added substance will take, or if supporting companies will withdraw due to rising costs.

• Market acceptance issues: Reformulation can impact a product's user experience, potentially leading to lower market acceptance.

Is it worth the risk?

“Delay techniques” are a gamble that can prove costly and uncertain. Investing in an uncertain future instead of formulated solutions is a risky strategy.

The alternative? Formulated solutions from Arxada

Instead of taking risks with "delay techniques," we offer you the adoption of our formulations. This can future-proof your business and may be a cost-effective solution that allows you to avoid expensive and risky reformulations.

• Our formulations are already notified/authorized in a variety of EU countries in line with the National Transitional Scheme of the BPR. 

• We offer a range of solutions tested to the current required standards.

• Support with Marketing and Regulatory expertise to aid obtaining National Registrations

 

Don't gamble with your company's future. Choose certainty and security with Arxada.